The mother of a six-year-old girl with a rare neurodegenerative disease has urged health bosses to "do the right thing" amid ...
Zacks Investment Research on MSN3d
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to TradeBioMarin Pharmaceutical (BMRN) closed the last trading session at $70.49, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...
The upcoming report from BioMarin Pharmaceutical (BMRN) is expected to reveal quarterly earnings of $0.73 per share, indicating an increase of 49% compared to the year-ago period. Analysts ...
BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN), a pharmaceutical company with a market capitalization of $13.15 billion, announced on Monday the appointment of Timothy P. Walbert to its ...
BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. BioMarin Pharmaceutical beat analysts’ revenue expectations by ...
BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback